Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective

Citations Over TimeTop 1% of 2022 papers

Abstract

Decentralized clinical trials (DCTs) have the potential to improve accessibility, diversity, and retention in clinical trials by moving trial activities to participants' homes and local surroundings. In this study, we conducted semi-structured interviews with 20 European regulators to identify regulatory challenges and opportunities for the implementation of DCTs in the European Union. The key opportunities for DCTs that were recognized by regulators include a reduced participation burden, which could facilitate the participation of underserved patients. In addition, regulators indicated that data collected in DCTs are expected to be more representative of the real world. Key challenges recognized by regulators for DCTs include concerns regarding investigator oversight and participants' safety when physical examinations and face-to-face contact are limited. To facilitate future learning, hybrid clinical trials with both on-site and decentralized elements are proposed by the respondents.

Related Papers

• → Diversity in the European Union(2009)18 cited
• → Reimagining Diversity: Moving from A Multicultural Perspective to An Ecological Perspective(2020)4 cited
• → Negotiating Unity and Diversity in the European Union(2020)6 cited
• Diversity in Biblical Perspective(2010)
• → From the Editor of Sexuality and Disability: Knowledge is Based upon Diversity of Thought and Perspective(2019)